How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?

Digestive and Liver Disease

Volumn 41, Issue 5, 2009, Pages 364-369

  Kim, B J ^a   Lee, K T ^a   Moon, T G ^a   Kang, P ^a   Lee, J K ^a   Kim, J J ^a   Rhee, J C ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Asymptomatic patient; CA 19 9; Pancreatic cancer; Tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CANCER SURGERY; COLON CANCER; DUODENUM CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PANCREAS CANCER; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCREENING TEST; THYROID CANCER;

ADULT; AGED; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; CLINICAL PROTOCOLS; DATA INTERPRETATION, STATISTICAL; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 63049112906     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.12.094     Document Type: Article

References (29)

1. Kim J.E., Lee K.T., Lee J.K., Paik S.W., Rhee J.C., and Choi K.W. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19 (2004) 182-186
2. Kodama T., Satoh H., Ishikawa H., and Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 21 (2007) 103-106
3. Kim H.J., Kim M.H., Myung S.J., Lim B.C., Park E.T., Yoo K.S., et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 94 (1999) 1941-1946
4. Ferrone C.R., Finkelstein D.M., Thayer S.P., Muzikansky A., Fernandez-delCastillo C., and Warshaw A.L. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24 (2006) 2897-2902
5. Goonetilleke K.S., and Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33 (2007) 266-270
6. Boeck S., Stieber P., Holdenrieder S., Wilkowski R., and Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70 (2006) 255-264
7. Kilic M., Gocmen E., Tez M., Ertan T., Keskek M., and Koc M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 49 (2006) 241-244
8. Tian F., Appert H.E., Myles J., and Howard J.M. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 215 (1992) 350-355
9. Safi F., Roscher R., Bittner R., Schenkluhn B., Dopfer H.P., and Beger H.G. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 2 (1987) 398-403
10. Tsao K.C., Hong J.H., Wu T.L., Chang P.Y., Sun C.F., and Wu J.T. Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal 21 (2007) 193-196
11. Kang C.M., Kim J.Y., Choi G.H., Kim K.S., Choi J.S., Lee W.J., et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140 (2007) 31-35
12. Safi F., Beger H.G., Bittner R., Buchler M., and Krautzberger W. CA 19-9 and pancreatic adenocarcinoma. Cancer 57 (1986) 779-783
13. Del Villano B.C., Brennan S., Brock P., Bucher C., Liu V., McClure M., et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29 (1983) 549-552
14. Mann D.V., Edwards R., Ho S., Lau W.Y., and Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26 (2000) 474-479
15. Parra J.L., Kaplan S., and Barkin J.S. Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci 50 (2005) 694-695
16. Kitagawa Y., Iwai M., Muramatsu A., Tanaka S., Mori T., Harada Y., et al. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues. Histopathology 40 (2002) 472-479
17. Reiter W., Stieber P., Reuter C., Nagel D., Lau-Werner U., Pahl H., et al. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res 17 (1997) 2935-2938
18. Reiter W., Stieber P., Reuter C., Nagel D., Lau-Werner U., and Lamerz R. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res 20 (2000) 5195-5198
19. Reiter W., Stieber P., Reuter C., Nagel D., Cramer C., Pahl H., et al. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 17 (1997) 2903-2906
20. Paganuzzi M., Onetto M., Marroni P., Barone D., Conio M., Aste H., et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 61 (1988) 2100-2108
21. Yamaguchi K., and Enjoji M. Adenoma of the ampulla of Vater: putative precancerous lesion. Gut 32 (1991) 1558-1561
22. Howaizi M., Abboura M., Krespine C., Sbai-Idrissi M.S., Marty O., and Djabbari-Sobhani M. A new cause for CA19.9 elevation: heavy tea consumption. Gut 52 (2003) 913-914
23. Schoniger-Hekele M., and Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci 51 (2006) 338-345
24. Roberts D.D., Monsein D.L., Frates Jr. R.C., Chernick M.S., and Ginsburg V. A serum test for cystic fibrosis using monoclonal antibody 19-9. Arch Biochem Biophys 245 (1986) 292-294
25. Tekin O. Hypothyroidism-related CA 19-9 elevation. Mayo Clin Proc 77 (2002) 398
26. Petit J.M., Vaillant G., Olsson N.O., Guignier F., Collignon S., Verges B., et al. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group. Gastroenterol Clin Biol 18 (1994) 17-20
27. Shimojo N., Naka K., Nakajima C., Ishizaki T., Okuda K., Murai J., et al. The effect of non-insulin-dependent diabetes on serum concentrations of tumor-associated carbohydrate antigens of CA19-9, CA-50, and sialyl SSEA-1 in association with the Lewis blood phenotype. Clin Chim Acta 190 (1990) 283-289
28. Dede M., Gungor S., Yenen M.C., Alanbay I., Duru N.K., and Hasimi A. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer 16 (2006) 189-193
29. Engelen M.J., de Bruijn H.W., Hollema H., ten Hoor K.A., Willemse P.H., Aalders J.G., et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 78 (2000) 16-20